54 results
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
21 Dec 20
Regulation FD Disclosure
7:04am
in oncology and further supports our commitment to provide innovative treatments to cancer patients with unmet medical needs. It is a key step for the Servier … for its development. Corporate growth is driven by Servier’s constant commitment in five areas of excellence: cardiovascular, immune-inflammatory
DEFA14A
EX-99.1
AGIO
Agios Pharmaceuticals Inc
21 Dec 20
Additional proxy soliciting materials
7:10am
in oncology and further supports our commitment to provide innovative treatments to cancer patients with unmet medical needs. It is a key step for the Servier … for its development. Corporate growth is driven by Servier’s constant commitment in five areas of excellence: cardiovascular, immune-inflammatory
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
12 Jul 22
Agios Appoints Brian Goff as Chief Executive Officer
4:14pm
. I look forward to working with him closely as he transitions into his new role and as I continue my commitment to Agios as chair of the board.”
“I am … Jackie for her incredible leadership and commitment to patients; she will undoubtedly continue to provide Agios and Brian with valuable strategic
DEFA14A
AGIO
Agios Pharmaceuticals Inc
21 Dec 20
Additional proxy soliciting materials
5:21pm
global pharmaceutical company with a deep commitment to expanding its emerging oncology portfolio. Servier is prepared to invest not only … of focus will shift, we’ll always be committed to the culture and values that have made us Agios. From our commitment to following the science to our
S-1
EX-10.13
AGIO
Agios Pharmaceuticals Inc
10 Jun 13
IPO registration
12:00am
right to defer making a DC Commitment pursuant to Section 3.6(d);
(b) if Celgene designates a confirmed Development Candidate for further Development … to defer making a DC Commitment pursuant to Section 3.6(d);
(c) such time as such Discovery Program becomes an Independent Program, Agios Reverted Program
8-K
EX-99.1
8safjb
2 Apr 21
Agios Announces Closing of Oncology Business Sale to Servier
4:47pm
8-K
EX-99.1
3dv2xgs70s3ixjniw
8 Dec 14
Agios Announces Celgene Decision to Extend Discovery Phase of Global Strategic Collaboration to April 2016
12:00am
8-K
EX-99.1
3hgjsqgz
12 Jan 15
Agios Announces that Celgene Has Agreed to Exercise its Option to License AG-120
12:00am
8-K
EX-99.1
zy7 da14x
13 Jun 14
Agios Pharmaceuticals Announces that Celgene Exercised its Option to License AG-221
12:00am
DEFA14A
8ebmsul3tf61a
23 Dec 20
Additional proxy soliciting materials
4:52pm
8-K
EX-99.1
344ipdt
21 Sep 20
Other Events
7:14am
8-K
EX-99.1
lotl9mc 84yovu5
13 Jan 14
Regulation FD Disclosure
12:00am
424B5
dnhk1ubaza lz5ce7
6 Nov 19
Prospectus supplement for primary offering
4:07pm
424B5
mg8f0op0
8 Nov 19
Prospectus supplement for primary offering
5:03pm
8-K
EX-99.1
thxn9rgvoujryb88m
16 Oct 15
Regulation FD Disclosure
12:00am
DEF 14A
s88rescp
7 Apr 14
Definitive proxy
12:00am
S-1
EX-3.1
uk0h1n7n98shqi0tpety
10 Jun 13
IPO registration
12:00am